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Abstract
Background: The hematopoietic stem cells (HSCs) niche of the bone marrow is comprised of
HSCs, osteoblasts, endothelial cells and a stromal component of non-hematopoietic multipotent
cells of mesenchymal origin named "mesenchymal stem cells" (MSCs).
Results:  Here we studied the global transcriptional profile of murine MSCs with immuno-
therapeutic potential and compared it with that of 486 publicly available microarray datasets from
12 other mouse tissues or cell types. Principal component analysis and hierarchical clustering
identified a unique pattern of gene expression capable of distinctively classifying MSCs from other
tissues and cells. We then performed an analysis aimed to identify absolute and relative abundance
of transcripts in all cell types. We found that the set of transcripts uniquely expressed by MSCs is
enriched in transcription factors and components of the Wnt signaling pathway. The analysis of
differentially expressed genes also identified a set of genes specifically involved in the HSC niche
and is complemented by functional studies that confirm the findings. Interestingly, some of these
genes play a role in the maintenance of HSCs in a quiescent state supporting their survival and
preventing them from proliferating and differentiating. We also show that MSCs modulate T cell
functions in vitro and, upon in vivo administration, ameliorate experimental autoimmune
encephalomyelitis (EAE).
Conclusion: Altogether, these findings provide novel and important insights on the mechanisms
of T cell function regulation by MSCs and help to cement the rationale for their application in the
treatment of autoimmune diseases.
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Background
Mesenchymal stem cells (MSCs) were first isolated from
bone marrow stroma and described initially as precursors
for fibroblasts [1]. More recently, their multi-lineage dif-
ferentiation capacity has been extensively characterized
[2]. It has been previously shown that MSCs are able to
differentiate into mature cells of multiple mesenchymal
tissues including chondrocytes, myocytes, adipocytes and
osteocytes in a process largely regulated by members of
the Wnt family of proteins [3]. MSCs are also an essential
component of the stromal scaffold of the bone marrow
that provides physical support during hematopoiesis.
Based on these findings, MSCs have been utilized to pro-
vide help for the engraftment of hematopoietic stem cells
(HSCs) in vivo [4]. Stromal cells from the bone marrow,
together with osteoblasts and endothelial cells, have been
involved in the formation of the so called HSC niche [5].
This can be defined as a specialized microenvironment
that precisely maintains a long-term storage of quiescent,
slowly dividing HSCs by preventing their proliferation,
differentiation or apoptosis [6,7].
Moreover, it has been recently shown that MSCs exert a
profound modulatory effect on immune cells by means of
both soluble and cell contact-dependent mechanisms [8-
10]. In particular, MSCs inhibit T and B cell proliferation
by halting cell cycle progression [11-13] and, under some
circumstances, also rescue T cells from apoptosis (Benve-
nuto, F. et al., unpublished observation). In a recent
experiment that highlights their therapeutic potential, in
vivo injection of MSCs ameliorated the course of chronic
progressive experimental autoimmune encephalomyelitis
(EAE), the animal model of multiple sclerosis [13].
Although MSCs are able to affect a wide array of immuno-
logical functions and, as a consequence, to control the
course of EAE, the underlying mechanism by which this
occurs remains largely unknown. However, it is likely that
both cell to cell contact and soluble factors are involved
supporting T cell inhibition in a non cognate fashion.
Among the latter, transforming growth factor-β1 (TGF-
β1) and hepatocyte growth factor (HGF) [8], indoleamine
2,3-dioxygenase (IDO) [14], and prostaglandin E2
(PGE2) [15] have been proposed as consistent candidates
but other studies have failed to reproduce these results
[10,16]. In order to identify a new set of genes suggestive
of their biological role, we used microarray technology to
examine the global transcriptional profile of MSCs
extracted from the bone marrow of C57BL/6J mice. We
applied bioinformatics tools to analyze our results in the
context of more than 400 publicly available expression
datasets and identified unique features of MSCs that are
likely responsible for their observed phenotype and
potential therapeutic properties. Based on our experimen-
tal results we discuss the possibility that the immunoreg-
ulatory properties of MSCs may be orchestrated by the
same mechanisms that are involved in the maintenance of
the HSC niche.
Results
In this study we evaluated the global transcriptional pro-
file of immunomodulatory MSCs and conducted a bioin-
formatics-based analysis to identify the possible
mechanisms for their unique properties. Since the process
of obtaining these cells involves a laborious, multi-step
cell culturing effort, prior to the transcriptional analysis
we tested our MSC enrichment protocol with functional
assays that tested their immunoregulatory and therapeutic
functions.
MSCs exhibit a distinctive capacity of controlling T cell 
proliferation and survival
We harvested MSCs from the bone marrow of C57BL/6J
mice and expanded them in culture until they reached a
stable CD45-CD44+Sca1+ phenotype by FACS-analysis
(data not shown). In order to test their capacity for mod-
ulating T cell functions, we added MSCs to mononuclear
cells (MNCs) that had been previously activated by incu-
bation with anti-CD3 antibodies. From as early as passage
7 in culture, MSCs inhibited T cell proliferation by induc-
ing cell cycle arrest. This was demonstrated by the
observed inhibition of CFSE incorporation (Fig. 1a) and
the accumulation of T cells in the G0 phase of the cycle
(Fig. 1b). When T cells are exposed to IL-2 prior to TCR
engagement with an anti-CD3 mAb, they undergo apop-
tosis, a phenomenon known as activation induced cell
death (AICD). As shown in Figure 1c, MSCs were able to
rescue T cells from apoptosis as they reduced the percent-
age of apoptotic T cells following AICD. Finally, we exam-
ined the in vivo immunosuppressive potential of MSCs by
injecting 1 × 106 cells into mice with MOG35–55-induced
experimental autoimmune encephalomyelitis (EAE). The
i.v. administration of 1 × 106 MSCs following disease
onset resulted in a statistically significant amelioration of
EAE clinical symptoms compared to PBS-injected control
mice (Fig. 1d). These results strongly suggest that MSCs
have a profound therapeutic effect on T cells not only by
preventing their proliferation but also by supporting their
survival. These findings are consistent with the dual func-
tion observed for bone marrow stromal cells, known to
inhibit HSC proliferation and, at the same time, support
their survival within the "niche" [4].
Therapeutic MSCs show a unique gene expression 
signature
We extracted total RNA from 7 cultured MSC samples
deriving from different mice and passages (see Methods)
with proven immunomodulatory ability, and analyzed
their gene expression profiles by hybridization onto
Affymetrix Mouse Genome 430 2.0 arrays. We then com-
pared these results to those reported in 486 publicly avail-BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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MSCs modulate T cell functions Figure 1
MSCs modulate T cell functions. (a) T cell stimulation leads to several cycles of cell division (left panel) while the co-cul-
ture with MSCs (middle and right panel) almost completely abrogates T cell proliferation and induces cell division arrest. (b) 
Ki67, a nuclear antigen associated with cell proliferation is downregulated on stimulated T cells when co-cultured with MSCs. 
(c) MSCs inhibit AICD as depicted by a decrease of total annexin V positive T cells (UR+LR quadrants). (d) Intravenous injec-
tion of MSCs ameliorates EAE. MSCs injected at day 10 post immunization, after disease onset ameliorates EAE (*p < 0.05). 
Arrow indicates day of MSC injection. EAE (filled triangles), controls (filled squares).BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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able platform-compatible microarrays exploring other 6
murine tissues (brain, heart, skeletal muscle, liver, kidney,
lung) and 6 cell types (dendritic cells, DCs, embryonic
stem cells, ESCs, embryonic fibroblasts, MEFs, neural
stem cells, NSCs, HSCs, T cells). We first used principal
component analysis (PCA), a dimensionality reduction
technique, with the goal of testing whether the expression
variance within tissues was smaller than that across tis-
sues. In this exploratory analysis we were able to observe
a recognizable segregation of samples according to the
source of their RNA. The distribution of samples in PCA
space was particularly pronounced for MSCs, which were
clearly separated from most other tissues and cell types
(Fig. 2a). Furthermore, the spread observed within princi-
pal components of MSCs was markedly lower than that
observed for arrays derived from brain or ESCs. We
hypothesize that although part of the observed pattern is
due to sample heterogeneity (arrays from brain were
obtained from several different laboratories and under
many different conditions), a true biological effect is pri-
marily responsible for the clear separation among groups
of arrays. A two-way hierarchical clustering analysis con-
firmed the PCA results and allowed us to identify groups
of genes characteristic of each tissue. In this analysis, MSC
signature was readily observed when we compared the
expression profile of ontogenically related cell types (Fig.
2b). Since MSCs are direct precursors of fibroblasts, it
would be expected that they exhibit some degree of simi-
larity. Interestingly, both analyses located samples from
these two cell types next to each other, suggesting an over-
all similarity in their expression patterns. Remarkably, the
unsupervised hierarchical clustering of samples resulted
in a nearly perfect sorting of samples by germinal layer of
origin (Fig. 2b). In addition to this, the striking similarity
between ESCs and NSCs at the transcriptional level is con-
sistent with previous reports [17]. These findings provide
further evidence that the genes selected for validation are
discriminatory, and that the in-silico analysis is sensitive
enough to detect the characteristic signature of each cell
type. Furthermore, the discriminatory power of these pro-
files seems to rely on a relatively small subset of genes.
Transcripts differentially expressed by MSCs belong to the 
HSC niche
In order to identify the characteristic signature of MSCs we
performed two types of analyses. First, we defined differ-
entially expressed transcripts as those expressed in all tis-
sues but showing statistically significant differences in
pair-wise comparison against MSCs. Our second analysis
focused on cell "specific" genes, that is those that were
detected in one but not in any other cell type. We found
403 differentially expressed genes between MSCs and any
given tissue or cell type in our panel [See Additional file
1]. Among these, galectin-1 (Lgals1) was the highest
expressed transcript in MSCs, a finding that correlates well
with previous reports [18,19]. We next sought to verify
whether high expression of Lgals1 was also a characteristic
of MSCs at the protein level. Indeed, the intracellular pres-
ence of Lgals1 colocalizing with MSC cytoskeleton was
detected by immunostaining and visualized by confocal
microscopy (Fig. 3). We then confirmed that Lgals1 is also
secreted by MSCs as demonstrated by its presence in MSC
supernatants measured by ELISA (Fig. 3). These results
provide further support for a biological role of the previ-
ously observed transcriptional signature of MSCs. Among
the transcripts with the highest signal intensities, we were
able to detect several hematopoiesis related molecules.
These transcripts code mostly for secreted proteins that
play a role within the HSC niche such as fibronectin-1
(Fn1), osteopontin (Spp1), chemokine C-X-C motif lig-
and-12 (Cxcl12), thrombospondin-1 (Thbs1), throm-
bospondin-2 (Thbs2), transforming growth factor-β2
(Tgfb2), angiopoietin-1 (Angpt1), insulin-like growth fac-
tor binding protein-4 (Igfbp4), fibroblast growth factor-7
(Fgf7), secreted frizzled-related protein-1 (Sfrp1), secreted
frizzled-related protein-2 (Sfrp2), dickkopf-3 (Dkk3), vas-
cular cell adhesion molecule-1 (Vcam1), and bone mor-
phogenetic protein receptor type 1a (Bmpr1a). The
expression of 4 representative genes from this list was val-
idated by quantitative RT-PCR using commercially
obtained RNA representing most tissues previously ana-
lyzed by microarray (Fig. 4). In general, there was good
agreement between the expression of the tested genes in
MSCs and other tissues and cell types (R2 = 0.7977), thus
confirming our observations. Unexpectedly, the expres-
sion of these genes was shared not only by MSCs and
MEFs, but also by DCs.
Transcripts uniquely expressed by MSCs are mostly 
transcription factors and genes downstream of the Wnt 
signaling pathway
In order to identify tissue-specific transcripts we next com-
puted a list with all the probes called "present" in the tis-
sue of interest and "absent" in all other tissues (see
Methods) [See Additional file 2]. Notably, the percentage
of genes identified as "specific" increased proportionally
with the ontological complexity of each tissue or cell type
(with the exception of heart). This is consistent with the
idea that a terminally differentiated cell needs to activate
the expression of a higher number of genes in order to
accomplish its specific tasks. As expected from a highly
specialized parenchymatous tissue, brain was the sample
with the highest percentage of specific genes. We next
compiled a list with the 381 resulting specific MSC genes
and ordered them according to signal intensity [See Addi-
tional file 3].
Interestingly, a sizable proportion of MSC specific genes
were either transcription factors or molecules belonging
to or downstream of the Wnt signaling pathway [3,20]BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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Therapeutic MSCs show a unique gene expression signature Figure 2
Therapeutic MSCs show a unique gene expression signature. (a) Principal component analysis of samples based on the 
expression of 500 genes. (b) Hierarchical clustering of genes and averaged samples utilizing smooth correlation metric with 
indication of the germinal layer of origin. MSCs: mesenchymal stem cells; MEFs: mouse embryonic fibroblasts; ESCs: embryonic 
stem cells; NSCs: neural stem cells; HSCs: hematopoietic stem cells; DCs: dendritic cells.BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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(Sfrp1, Tcf3, Rarg, Cspg2, Dvl2, Axin1). Wnt proteins are
highly conserved, lipid-modified secreted ligands that
influence multiple processes in animal development. In
particular, they mediate important decisions between pro-
liferative self-renewal and differentiation of stem cells.
The average signal intensity of these genes was also mark-
edly lower than the intensity of most differentially
expressed genes suggesting that these transcripts are
expressed at low levels.
Gene Ontology (GO) statistical analysis of genes 
differentially and uniquely expressed by MSCs
In order to integrate expression profiles into a functional
framework we performed a GO-based statistical analysis.
When we analyzed the 403 differentially expressed genes,
we found that extracellular matrix and extracellular were
among the first three statistically significant GO Cell
Component categories, while cell adhesion was among the
first five most enriched Biological Process classes (Fig. 5).
This suggests that the most abundantly expressed tran-
scripts were mainly secreted proteins, a significant part of
which are involved in cell-cell contact. Conversely, when
we analyzed the list of "specific" genes, they appeared to
be primarily located in the nucleoplasm  and mainly
involved in development and transcription processes (Fig.
5). This strongly suggests that the list of "specific" genes is
composed mainly by low level-expressed transcription
factors and molecules involved in development (i.e. Wnt
pathway).
Discussion
Overall, this report provides a transcriptional map of
immunomodulatory MSCs through global RNA profiling
and bioinformatics-based comparative analysis with sev-
eral other mouse tissues and cell types. By analyzing arrays
from the same platform (Affymetrix 430) we were able to
Expression of galectin-1 Figure 3
Expression of galectin-1. Immunocytochemistry staining of galectin-1 (red, a) beta-tubulin (green, b), and merged image (c). 
(d) Dosage of galectin-1 by ELISA at different concentrations of MSCs.BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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Validation of microarray results Figure 4
Validation of microarray results. (a) Microarray levels (grey bars) represent the signal intensity of probe-sets correspond-
ing to the same gene (averaged when more than one present). qRT-PCR data (black bars) are obtained utilizing a GAPDH 
standard curve. Relative expression levels with respect to those of MSCs are shown. (b) Correlation between microarray (X 
axis) and qRT-PCR (Y axis) expression values (fold-differences versus MSCs). triangles = Spp1, circles = Fn1, diamonds = Thbs1, 
squares = Thbs2, violet = Heart, red = Brain, yellow = Lung, rose = Kidney, orange = DCs, green = MEFs, tan = NSCs, grey = 
T cells, blue = ESCs, gold = Muscle, turqoise = Liver.BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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perform statistical analyses combining results across dif-
ferent laboratories. Thus, we overcame the limitation of
comparisons across different platforms, generally
regarded as problematic from a biological perspective
because the measurements may represent different physi-
cal quantities [21]. Conversely, the approach used in this
study offers a more precise assessment of the true degree
of differential expression and helps refine the list of can-
didate genes warranting biological validation.
By applying principal component and hierarchical cluster-
ing analyses, we identified a distinctive gene expression
profile for MSCs. MSC gene expression profile appeared in
fact to be characteristic and substantially homogeneous.
One of the most significant findings of this analysis was
the nearly perfect sorting of tissues by germinal layer of
origin utilizing an unsupervised classification. As
expected, being MEFs derived from MSCs, their expression
profile was highly similar. Furthermore, previous studies
have shown that cultured MEFs maintain some of the
multipotency of MSCs [22]. Surprisingly, MSCs and DCs
displayed a similar profile as well, a finding further con-
firmed by qRT-PCR analysis. We speculate this could be
due to the fact that both MSCs and DCs are involved in
the determination of bystander cell fate, respectively HSCs
and T cells, by cell-cell contact-dependent mechanisms.
When focusing on the list of differentially expressed genes
we found that many of them had been reported in previ-
ous transcriptional studies of MSCs, thus validating the
sensitivity and reproducibility of our approach [18,23].
Among MSC specific genes, several proteins belonging to
the Wnt signaling pathway or Wnt-regulated genes (Sfrp1,
Dvl2, Axin1, Tcf3, Rarg, Cspg2, Efnb2) were detected. Wnt
GO statistical analysis Figure 5
GO statistical analysis. GO statistical analysis of the most enriched Cell Component (left) and Biological Process (right) cat-
egories for differentially expressed genes (grey bars) and specific genes (black bars).BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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proteins have been previously reported to promote myo-
genesis [24], inhibit chondrogenesis [25] and adipogene-
sis [26] and to have a dual effect on osteogenesis [27].
Some of the most abundantly expressed genes are also
inhibitors (Sfrp1, Sfrp2, Dkk3) or act downstream (Thbs1,
Thbs2, Cyr61, Sema3a, Sfrp2) of the Wnt signaling path-
way [20]. Among the differentially expressed genes we
were also able to find most recently described molecules
involved in stem cell renewal such as Dkk3  [28] and
Serpinf1 (PEDF) [29]. Altogether, these results are consist-
ent with the involvement of Wnt signaling in mesenchy-
mal lineage specification.
We also used GO-based functional classification to char-
acterize both differentially expressed and MSC specific
genes. This analysis confirmed our primary observation
that differentially expressed transcripts were significantly
enriched in molecules present in the extracellular space
and involved in cell adhesion process. On the other hand,
MSC specific genes were mainly nucleoplasm-located
transcription factors involved in development. Impor-
tantly, the observation that these transcription factors are
expressed at low levels is consistent with most recent find-
ings about the biology of ESCs. These cells have been
recently shown to express low levels of transcription fac-
tors by means of the polycomb group proteins and by spe-
cific chromatin modification patterns thus keeping them
poised for activation during development [30]. It can be
speculated that a similar mechanism may be working in
further committed stem cells such as MSCs.
The combined transcriptional and comparative analyses
presented here allowed us to identify several secreted mol-
ecules that may be critical in determining cell functions.
Several of these molecules have been previously reported
to play a pivotal role in the constitution of the HSC niche
synapse [5] or as being expressed by hematopoiesis-sup-
portive stromal cells [31] [See additional file 4]. For exam-
ple, angiopoietin-1 (Angpt1) is considered one of the
major regulators of blood vessel stability [32]and, in con-
trast with angiopoietin-2 (Angpt2), it seems to exert a
potent anti-inflammatory effect [33]. Moreover, Angpt1
and its receptor endothelial-specific receptor tyrosine
kinase(Tek) are known key components of the HSC niche,
namely of the cell-cell signaling between osteoblasts and
HSCs. Furthermore, Angpt1 is likely to be one of the most
important molecules in the induction of the "quiescent"
state of the HSCs, by enhancing their tight adhesion to
osteoblasts, inhibiting cell division, arresting cells in the
G0 phase of the cell cycle and promoting cell survival
under myelosuppressive stress [34].
Osteopontin (Spp1) is a highly acidic phosphoprotein
with pleiotropic effects, including regulation of inflam-
mation, cell adhesion and angiogenesis [35]. In addition,
it has recently been demonstrated to be a pivotal molecule
in limiting the size of the HSC pool [36]. Similarly, it has
also been shown that the thrombin-cleaved form of Spp1
promotes the quiescence of HSCs by exerting a profound
suppression of proliferation of HSCs without inducing
apoptosis [37]. Interestingly, Spp1-deficient mice devel-
oped a milder form of EAE, and activated T cells from
these animals produced less IFNγ and more IL-10 than
their wild type counterparts consistently with the role of a
pro-inflammatory molecule [38]. Although an elevated
Spp1 expression in therapeutic MSCs is in apparent con-
tradiction with its previously reported proinflammatory
role, its pleiotropism and ubiquitousness suggest that it
may interact with different receptors at different times and
through different regulatory networks, thus preventing a
straightforward characterization of its biological func-
tions.
Thrombospondin (Thbs)-1 and -2 are extracellular matrix
proteins that share several effects on cell growth, adhe-
sion, survival and differentiation. In particular, Thbs1,
secreted by DCs, has been demonstrated to inhibit both
TCR signaling and T cell proliferation, mainly acting
through the CD47 receptor [39]. In addition, Thbs1 has
also been described as part of the HSC niche [40]. Both
Thbs1 and, to a lesser extent, Thbs2 have been studied as
inhibitors of endothelial growth [41]. On the other hand,
Thbs2 has been described as an autocrine inhibitor of pro-
liferation secreted by MSCs which acts through cell-cycle
inhibition without the induction of apoptosis [42].
Fibronectin-1 (Fn1) is another major component of the
bone marrow stroma. The interaction of Fn1  with β1-
integrins, VLA-5 in particular, has been shown to be a neg-
ative regulator of HSC proliferation by preventing them
from entering the cell cycle [43].
Galectin-1 (Lgals1) is an endogenous lectin characterized
by its affinity for beta-galactosides which has been dem-
onstrated to exert an immunosuppressive effect on T cells
through both apoptotic and non-apoptotic mechanisms
[44]. This molecule has been shown to be expressed by
hematopoietic-related tissues [23] and to inhibit HSC
growth particularly at high concentrations [45]. Most
recently, Lgals1 has been shown to play a role within the
NSC niche [46]. We were able to confirm MSC expression
of this molecule both by ELISA and immunocytochemis-
try assays.
Finally, semaphorins are molecules that were originally
identified as mediators of axon guidance but have also
been described as part of the immunological synapse [47].
Semaphorin 3A (Sema3a), in particular, has also been
recently demonstrated to mediate T cell proliferation inhi-BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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bition by arresting T cells in the G0/G1 phase of the cell
cycle [48].
Conclusion
Here we have shown that MSCs arrest T cells in the G0
phase of the cell cycle. These results are in line with previ-
ous reports showing that MSCs induce T cell [12], B cell
[11] and dendritic cell division arrest anergy [49]. Such
effect not only does not depend on the induction of apop-
tosis on immune cells [13] but is accompanied by an anti-
apoptotic effect on target cells, when they are overstimu-
lated. Although this dual in-vitro effect of MSCs on T cells
appears counterintuitive as the mechanism responsible
for ameliorating EAE, we speculate that MSCs may exert
their immunoregulatory action by virtue of their anti-pro-
liferative effect, while their anti-apoptotic action is mostly
beneficial for the survival and protection of neural cells.
Recent data seem to support this hypothesis [50].
Our data clearly shows that immunomodulatory MSCs
abundantly express several molecules also secreted by
osteoblasts in the context of the HSC niche synapse where
they may keep HSCs quiescent while supporting their sur-
vival. In addition, some of these molecules belong to the
protein class of matricellular proteins (Spp1, Thbs1, Thbs2,
Sparc), namely extracellular matrix proteins that, rather
than serving a primary structural role, mediate both tissue
morphogenesis and homeostasis modulating cell-matrix
and cell-cell interactions and other important processes
such as cell growth, angiogenesis and inflammation. This
observation, together with the similarities we found
between MSC and DC transcriptomes, highlights the rele-
vance of macromolecular assemblies at the interface
between MSCs and surrounding cells. We hypothesize
that, the interactions between MSCs and HSCs resemble
those described for the immunological synapse thus lead-
ing to quiescence both of proliferating HSCs and immune
cells. Therefore, given the analogies between the effect
exerted by osteoblasts on HSCs and by MSCs on immune
cells, we propose that the same bystander mechanisms
may play a role in both types of cell-cell interaction (Fig.
6). At the same time, interaction between MSCs, their
extracellular matrix components and differentiating
somatic cells is an established mechanism within stem
cell niches throughout the body [51]. Based on our exper-
imental results, we also hypothesize that MSCs represent
fundamental niche cells within the bone marrow and
potentially other stem cell niches as well. In particular,
when administered in vivo, they could participate in the
formation and modulation of the recently named "atypi-
cal ectopic perivascular niches" in the context of inflam-
matory disorders of the CNS [52]. Overall, our data shed
further light into the biology of MSCs by proposing sev-
eral candidate molecules as potential mediators both of
the HSC niche-supportive and immunomodulatory activ-
ities of MSCs.
Methods
MSC isolation and expansion
MSCs were isolated and expanded from C57BL/6J mice as
described elsewhere [13]. Briefly, bone marrow from 6- to
8-week-old mice was flushed out of tibias and femurs and
plated in murine MesenCult (StemCell Technologies,
Vancouver, BC) at the concentration of 0.3 to 0.4 ×
106cells/cm2. When 80% confluent, adherent cells were
trypsinized, harvested and then replated in order to
expand them until a homogeneous population was
obtained in about 4 to 5 weeks. The phenotype of MSCs
was analyzed by cell surface analysis using the FACS
Canto flow cytometer as previously described [13]. The
following monoclonal antibodies directed against mouse
surface markers anti-CD45 cytochrome C (CyC), anti-
stem cell antigen-1 (Sca-1) phycoerythrin (PE), unconju-
gated anti-CD9, anti-CD3 CyC, anti-CD4 peridinin chlo-
rophyll-alpha protein (PerCP), anti-CD73 PE were
purchased from Pharmingen/Becton Dickinson. The phe-
notype of MSCs was routinely verified by flow cytometry
using the following combination of antibodies: CD11b
FITC/CD34 PE/CD45 CyC and CD9 FITC/Sca-1 PE/CD45
CyC.
In vitro and in vivo immunomodulatory experiments
Mononuclear cells (MNCs) were obtained from the
spleen and the lymph nodes of healthy C57BL/6J mice
and isolated by ficoll gradient (Lympholite, Cedarlane,
Hornby, ON). MNCs were then utilized for standard pro-
liferation assays as described elsewhere [13]. T cell prolif-
eration was evaluated by CFSE incorporation by dividing
CD3 positive cells. In order to study the phase of T cell
cycle, we evaluated the intracellular expression of Ki67, a
nuclear antigen associated with cell proliferation, present
throughout the active cell cycle (G1, S, G2 and M phases)
but absent in resting cells (G0). For the induction of apop-
tosis, 2 × 106 MNCs were pretreated with 100 U/ml of IL-
2 for three days and were subsequently overstimulated
with 5 µg/ml of anti-CD3 for 4 days in the presence or
absence of MSCs at 1:1 ratio in a 96 well plate. The
number of apoptotic T cells that underwent activation
induced cell death (AICD), has been studied analyzing the
number of annexin V positive cells by flow cytometry gat-
ing on CD3 positive cells.
EAE experiments were carried out as described elsewhere
[13]. On day fifteen post-immunization, usually consid-
ered the peak of disease, mice received intravenous 1 × 106
MSCs diluted in PBS. Controls received intravenous injec-
tions of an equal volume of PBS on the same day. Clinical
score was assigned daily according to the standard and
validated scale from 0 to 5. Disease incidence, onset, andBMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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maximum score were recorded for each mouse and
expressed as mean ± SD.
Gene expression profiling
Seven immunomodulatory MSC cultures obtained
between the 7th and the 12th passage in culture were ana-
lyzed for gene expression. Total RNA was isolated from
confluent cultured cells using TRIzol reagent and further
cleaned up with RNeasy Mini kit (Qiagen). RNA was then
amplified and labeled for hybridization onto Affymetrix
Mouse Genome 430 2.0 arrays according to the manufac-
turer's instructions (Affymetrix, Inc. Santa Clara, CA). All
seven samples were hybridized washed and scanned at the
TGen microarray core facility (Phoenix, AZ).
Microarray data analysis
In addition to the MSC arrays generated in our lab, we
also analyzed other 486 Affymetrix Mouse Genome 430A,
430B and 430 2.0 arrays corresponding to 6 murine tis-
sues (brain, n = 90; heart n = 73; kidney n = 21; liver n =
72; and skeletal muscle n = 58). We also analyzed public
arrays from 6 murine cell types (T cells n = 14; dendritic
cells, DCs, n = 6; embryonic stem cells, ESCs, n = 60;
embryonic fibroblasts, MEFs n = 44; neural stem cells,
NSCs n = 20, and hematopoietic stem cells, HSCs n = 4).
All the publicly available expression sets (including our
own) can be downloaded from the Gene Expression
Omnibus website [53], with their respective GEO acces-
sion numbers [See Additional file 5]. The raw intensity of
individual samples was imported into BRB-Array Tools
(Biometric Research Branch, National Institutes of Health,
Bethesda, MD). Expression data was normalized by com-
puting the median of the intensity distribution frequency
for each array. Only genes showing at least a 4-fold change
from that gene's median value on 20% or more of the
arrays were considered for subsequent analysis. For statis-
tical significance of all class comparisons, we performed F
tests with a nominal value of p < 0.0001, and corrected the
Model of MSC-T cell interactions Figure 6
Model of MSC-T cell interactions. Fn1: fibronectin-1, Spp1: osteopontin, Cxcl12: chemokine C-X-C motif ligand-12, Thbs1: 
thrombospondin-1, Angpt1: angiopoietin-1, Vcam1: vascular cell adhesion molecule-1, Lgals1: galectin-1, Sema3a: semaphorin-
3A, Nrp1: neuropilin-1, Cxcr4: chemokine C-X-C motif receptor-4, Tek: endothelial-specific receptor tyrosine kinase, Itga4: 
integrin alpha-4 (VLA-4), Ptprc: protein tyrosine phosphatase receptor type-C (CD45).BMC Genomics 2007, 8:65 http://www.biomedcentral.com/1471-2164/8/65
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for multiple comparisons using the FDR (false discovery
rate) method. For principal component analysis and hier-
archical clustering, the raw intensity data were exported to
GeneSpring GX software (Agilent Technologies Inc, Palo
Alto, CA). To define the list of "specific" genes we utilized
399 arrays which expressed the probe-set call, namely an
absolute analysis that indicates if the transcript is present
(P), absent (A) or marginal (M). We then defined a tran-
script as detected when it was called "P" or "M" in at least
70% of the arrays from every tissue or cell type. We
imported these data into Microsoft Access to obtain a list
of "specific" genes, namely genes detected only in MSC
arrays and not in other tissues or cell types.
Gene ontology analysis
Selected gene lists were annotated using open source EASE
version 2.0 gene ontology (GO) analysis software [54].
For each GO group, EASE computed the number of genes
represented on the microarray for that group and the sta-
tistical significance p value for each gene in the group.
These  p  values reflect differential expression among
classes and were computed based on Fisher's exact proba-
bility test controlled by FDR. We considered the abun-
dance of a GO category significantly different if either
significance level was < 0.01.
Quantitative RT-PCR
Murine total RNA from liver, brain, heart, lung and kidney
was purchased from Ambion Inc (Austin, TX). Murine
skeletal muscle total RNA was purchased from Stratagene
(La Jolla, CA). Primary MEFs were purchased from Stem-
Cell Technologies (Vancouver, BC). RNA was isolated
from murine T cells, DCs, ESCs, NSCs and MEFs using
RNeasy Mini kit (Qiagen, Valencia, CA) and cleaned up
with RNase-Free DNase Set (Qiagen, Valencia, CA). Total
RNA was reverse transcribed using Multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA). The
TaqMan gene expression arrays and the TaqMan Universal
Master Mix were used according to the manufacturer's rec-
ommendations (Applied Biosystems). Measurement and
analysis of gene expression were performed using the ABI
Prism 7900HT Sequence Detection System software
(Applied Biosystems). Content of cDNA samples was
obtained by utilizing the GAPDH relative standard curve
method as described elsewhere [55].
Direct Enzyme-Linked Immunosorbent Assay for galectin-
1 (Lgals1)
Supernatants from MSC cultures were repeatedly spinned
down at 3500 g through 10 and 30 kDa cut-off filters in
Centricon tubes (YM-10, YM-30 Millipore Corporation,
Bedford, MA) to increase detection of Lgals1 (around 14
kDa) and incubated in MaxiSorp plates (Nunc, Rochester,
NY) at 4°C overnight. Upon washing, Lgals1 was directly
detected by incubation with an anti-Lgals1 monoclonal
biotinylated antibody (R&D Systems, Minneapolis, MN)
for 2 hours at room temperature and, subsequently, with
streptavidin-HRP (R&D Systems, Minneapolis, MN) for
20 minutes at room temperature. Following the addition
of the TMB substrate, optical densities were measured at
450 nm in an ELISA reader (Metertech INC, Taiwan).
Immunofluorescence
MSCs were plated in chamber slides (Lab Tek II, chamber
slide system, Nalge Nunc, Naperville, IL) at the concentra-
tion of 104 cells/well and then incubated at 37°C in 5%
CO2 for three days. Next, cells were fixed in 4% PFA,
washed in PBS with 1% BSA (Sigma Aldrich, St. Louis,
MO) at room temperature for 5 minutes and blocked with
a blocking buffer (20% donkey serum and 0.05% tween
20 in PBS with 1% BSA) for 30 minutes at room tempera-
ture. In each well we added the mouse anti-Lgals1 anti-
body (2 µg/ml, R&D Systems Minneapolis, MN) and
mouse anti-beta-tubulin antibody (2 µg/ml, Chemicon,
Temecula CA) and the slides incubated in a humid cham-
ber overnight at 4°C. These antibodies were revealed
respectively with an Alexa 546 conjugated secondary anti-
body (1 µg/ml, Molecular Probes, Eugene, OR) and with
Alexa 488 conjugated secondary antibody (1 µg/ml,
Molecular Probes, Eugene, OR) for 30 minutes at room
temperature, followed by washing in PBS. The chamber
slides were mounted with "VECTASHIELD Mounting
Medium with DAPI" (Vector Laboratories, Burlingame
CA). The chamber slides were analyzed by confocal
microscopy (Leica TCS SP2 AOBS Systems, Leica
microsystems, Heidelberg GmbH).
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